Pallas Health vs Willow: Online GLP-1 care compared
Pallas Health vs Willow: quick verdict. Pallas centers on clinician-chosen brand or compounded GLP-1 with a low compounded intro price, while Willow emphasizes an oral GLP-1 program plus structured progress tracking and follow-up. For a fast decision, choose Pallas for clinician-selected brand or compounded injections and lower compounded intro pricing, or Willow for a telehealth program built around progress tracking and behavioral support.
See Pallas Health plans and pricing
Pallas Health vs Willow: what differs most
This direct comparison focuses on the most distinctive supported differences: medication format and choices, pricing structure, care and support model, compounded medication regulatory notes, and eligibility or clinician review. The comparison uses only supplied facts and preserves qualifiers exactly.
1. Medication format and choices
Pallas Health offers FDA-approved brand-name Wegovy, Ozempic, Zepbound and Mounjaro, plus clinician-personalized compounded semaglutide and tirzepatide prepared in the USA when a brand medication is not the right fit. Willow positions an oral GLP-1 program and highlights that medication-specific approval status must be confirmed. Willow also notes that compounded medications, when offered, are not FDA-approved.
2. Pricing and how plans renew
Pallas lists compounded semaglutide as $139 first month, then $597 every 12 weeks which is a $199/month average, and compounded tirzepatide $179 first month then $897 every 12 weeks which is a $299/month average. Pallas also lists cash-pay brand prices on its site for Wegovy, Zepbound, Ozempic and Mounjaro. Willow shows a starting price of 299 in captured evidence but landing-page details were not fully readable. The supplied evidence states Willow has higher monthly entry pricing for some plans.
Explore Willow program details
3. Care delivery and support
Pallas is 100% online with one all-in plan price that includes clinician review, ongoing check-ins and care-team messaging, with no membership fee. Pallas is asynchronous in most states, with a video visit required in seven states plus Washington, D.C., and care-team hours are weekdays 9 AM to 5 PM ET. Willow is telehealth-first and emphasizes progress tracking tools and follow-up consultations, describing a structured weight management journey that pairs medication with behavioral scaffolding intended to support long-term outcomes.
4. Regulatory and safety notes
Both sources preserve important qualifiers about compounded medication. Pallas explicitly states that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality and that Pallas does not manufacture or compound medication. Willow notes that medication-specific approval status must be confirmed and that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
5. Eligibility and clinician review
Pallas repeatedly states that eligibility is determined by a US-licensed clinician and that treatment is cash-pay only. Willow states treatment is available only when a licensed clinician determines it is medically appropriate.
Side-by-side at a glance
| Criteria | Pallas Health | Willow |
|---|---|---|
| Medication options | Brand-name GLP-1s and clinician-personalized compounded semaglutide or tirzepatide | Oral GLP-1 program; medication-specific approval status must be confirmed |
| Starting price (captured) | Compounded semaglutide $139 first month; then $199/mo avg | 299 (captured starting price) |
| Care model | 100% online; clinician review, check-ins and messaging included; asynchronous in most states | Telehealth-first with progress tracking and follow-up consultations |
| Compounded meds | Compounded in the USA; not FDA-approved; prepared by US-licensed compounding pharmacies | Compounded medications, when offered, are not FDA-approved |
| Insurance and billing | Cash-pay only; does not bill insurance; FSA/HSA may need Letter of Medical Necessity | Not supplied in captured evidence |
Pallas Health vs Willow: detailed implications
If medication choice matters, Pallas documents both brand pens and compounded injections and says a US-licensed clinician will personalize the plan. If you prioritize structured behavioral support and progress tracking around an oral option, Willow emphasizes follow-up and tracking tools as core features. For pricing clarity about compounded injections, Pallas supplies explicit first-month and renewal figures; Willow shows a captured starting price but full pricing details were not readable on the captured page.
Check Pallas Health clinician-reviewed options
Final comparison and recommendation
Both programs require clinician determination of eligibility and preserve the regulatory qualifier that compounded medications are not FDA-approved. Pallas is a 100% online program offering brand and compounded GLP-1s with detailed compounded pricing starting at $139 first month then $199/month average. Willow is telehealth-first with progress tracking and follow-up support and a captured starting price of 299, with limited landing-page detail captured.
Choose Pallas Health if you want a clinician to choose between brand-name pen medications and a per-patient compounded preparation, prefer a fully online asynchronous workflow in most states, and value the documented compounded pricing structure. Choose Willow if you want a telehealth-first program that emphasizes oral GLP-1 delivery, progress tracking and structured follow-up support and accept that full pricing and landing-page details were not fully readable in captured evidence.